India Made AstraZeneca's COVID-19 Vaccine Not Eligible For EU Travel, Seeks Resolution: Reuters


MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO

As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off.  Claim your 50% discount here.


  • Serum Institute of India's (SII) CEO Adar Poonawalla said he was trying to resolve EU travel problems facing Indians inoculated with SII's licensed version of AstraZeneca Plc's (NASDAQ:AZN) COVID-19 vaccine.
  • "I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries," Poonawalla said on Twitter.
  • India's Ministry of External Affairs has raised Covishield's lack of recognition by the European Medicines Agency (EMA).
  • The EMA said the only COVID-19 vaccine from AstraZeneca for which a marketing authorization application had been submitted and evaluated was Vaxzevria.
  • Covishield does not currently have marketing authorization in the EU, even though it may use a similar production technology to Vaxzevria, the agency said.
  • In addition to the AstraZeneca shot in the region, the other EU-recognized vaccines are those made by Moderna Inc (NASDAQ:MRNA), Pfizer Inc (NYSE:PFE) - BioNTech SE (NASDAQ:BNTX), and Johnson & Johnson (NYSE:JNJ).
  • A European Union vaccine passport program will allow people to travel freely within the bloc from July 1, as long as they have had one of four Western-made vaccines.
  • In April, Reuters reported that the EU was seeking 10 million Covishield doses from SII to meet a shortfall before India halted all exports amid a domestic infection surge. 
  • Price Action: AZN shares are up 1.03% at $59.96 during the market session on the last check Monday.

MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO

As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off.  Claim your 50% discount here.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechGovernmentNewsHealth CareFDAGeneralBriefsCOVID-19 VaccineReuters